Mucoadhesive Multiparticulate Drug Delivery Systems: An ExtensiveReview of Patents

Innovations in pharmaceutical research are striving for designing newer drug therapies toeradicate deadly diseases. Strategies for such inventions always flourish with keys and objectivesof minimal adverse effects and effective treatment. Recent trends in pharmaceutical technologyspecify that mucoadhesive drug delivery system is particularly appropriate than oral controlrelease, for getting local systematic delivery of drugs in GIT for an extended interval of time ata predetermined rate. However, it is somehow expensive and unpleasant sensation for somepatients, but still it is needful for getting short enzymatic activity, simple administration withoutpain and evasion of fast pass metabolism. Usually the vehicles employed in drug delivery ofmucoadhesive system have a significant impact that draws further attention to potential benefitslike improved bioavailability of therapeutic agents, extensive drug residence time at the site ofadministration and a comparatively faster drug uptake into the systemic circulation. The drugrelease from mucoadhesive multiparticulates is contingent on several types of factors comprisingcarrier need to produce the multiparticles and quantity of medication drug contained in them.Mucoadhesion is characterized by selected theories and mechanisms. Various strategiesemergent in mucoadhesive multiparticulate drug delivery system (MMDDS) by in-vitro as wellas ex-vivo description and characterization are also critically discussed. Apart from these, theprimary focus during this review is to highlight current patents, clinical status, and regulatorypolicy for enhancement of mucoadhesive multi-particulate drug delivery system in the present scenario.